Sai Parenteral's Ltd

Sai Parenterals Limited announced that its subsidiary, Noumed Pharmaceuticals Pty Limited, has renewed a long-term Over-the-Counter (OTC) Medicines Supply Agreement with a leading Australian pharmacy chain, featuring an expanded product portfolio and a three-year term. The renewed agreement is valued at AUD 30 million, which equates to approximately Rs 204 Crores based on an exchange rate of Rs 68.52 per AUD, and does not involve any related party transactions or interest from the company's promoters or group entities. The effective date of the agreement is August 24, 2026.

Sai Parenterals Ltd share price declined by 1.35% to Rs 579.4 after the company's net profit plunged by 39.82% to Rs 7.92 crore, while revenue from operations slipped slightly by 9.73% to Rs 178.67 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, gaining 4.41%. It has improved by 1.16% over last one week and advanced by 11.70% in last one month while the market capitalization of Sai Parenterals Ltd has gained 11.76% and 20.76% in the same period respectively. Profit before tax (PBT) of Sai Parenterals Ltd stood at Rs 9.79 crore in Q2 FY26, jumping 387.06% year-on-year, and crashing by 20.98% quarter-on-quarter. EBITDA came in at Rs 20 crore, surging by 452.51% YoY and dropping 14.78% sequentially. Total expenses softened by 9.31% to Rs 163.26 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 116.12 crore, growing marginally by 1.73% YoY, while employee benefits expense was at Rs 11.54 crore, registering a marginal contraction of 5.56% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 6.08% to Rs 163.11 crore, while net profit saw a strong growth of 71.38% to Rs 14.43 crore, compared to previous TTM. EBITDA jumped by 2802% to Rs 38.74 crore, and PBT soared 58.52% to Rs 19.91 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 33.15 crore in FY26, as against Rs 29.76 crore in FY25.

Sai Parenterals Limited informed the Bombay Stock Exchange and National Stock Exchange that there were no deviations or variations in the utilization of proceeds from its Initial Public Offer (IPO) during the quarter ended June 30, 2026, as per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had raised Rs 2,850 million through the IPO from March 24, 2026, to March 27, 2026.

Sai Parenterals Limited will hold a board meeting on Tuesday, August 11, 2026, at its registered office to consider unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026, and a limited review report (standalone and consolidated) for the same period, according to a filing with the BSE Limited and NSE Limited.

Sai Parenterals announced that the company's subsidiary Noumed Pharmaceuticals had entered OTC medicines supply agreement with Australia's leading pharmacy network with contract valued at Australian Dollars (AUD) 202 millions (equivalent to Rs 1300 crore; 1 AUD = INR 64.5). The agreement is valid for a period of 7.5 years with a further option of 3 years extension upon mutual consent.

Sai Parenterals has received a purchase order valued at USD 11 million at an exchange rate of Rs 95 (Rs 104.50 crore) from PILL CORP, Bulacan, Philippines. The contract is for supply of anti TB products for the Philippines market on exclusivity basis for a period of 10 years.

Sai Parenteral's will hold a meeting of the Board of Directors of the Company on 23 May 2026.

Sai Parenterals will hold a meeting of the Board of Directors of the Company on 20 April 2026.

Sai Parenteral's will hold a meeting of the Board of Directors of the Company on 20 April 2026.

The equity shares of Sai Parenterals (Scrip Code: 544742) are listed effective 02 April 2026 and admitted to dealings on the exchange in the list of ''B'' group securities. At 09:09 IST, the pre-open indicative price of the stock was at a premium of 1.79% to the IPO price of Rs 392.